Article
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.
Haematologica - 1 May 2018
Ferret Yann, Boissel Nicolas, Helevaut Nathalie, Madic Jordan, Nibourel Olivier, Marceau-Renaut Alice, Bucci Maxime, Geffroy Sandrine, Celli-Lebras Karine, Castaigne Sylvie, Thomas Xavier, Terré Christine, Dombret Hervé, Preudhomme Claude, Renneville Aline
Abstract excerpt
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia, since these mutations collectively occur in 15-20% of cases of acute myeloid leukemia and now represent druggable targets. We employed droplet digital polymerase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.